Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 4
2023 5
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.
Prosz A, Sahgal P, Huffman BM, Sztupinszki Z, Morris CX, Chen D, Börcsök J, Diossy M, Tisza V, Spisak S, Likasitwatanakul P, Rusz O, Csabai I, Cecchini M, Baca Y, Elliott A, Enzinger P, Singh H, Ubellaker J, Lazaro JB, Cleary JM, Szallasi Z, Sethi NS. Prosz A, et al. NPJ Precis Oncol. 2024 Apr 8;8(1):87. doi: 10.1038/s41698-024-00561-6. NPJ Precis Oncol. 2024. PMID: 38589664 Free PMC article.
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Cecchini M, Zhang JY, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein SM, Kortmansky J, Johung KL, Bindra RS, LoRusso P, Schalper KA. Cecchini M, et al. Cancer Res Commun. 2023 Jun 28;3(6):1132-1139. doi: 10.1158/2767-9764.CRC-23-0045. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37387791 Free PMC article.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Cecchini M, et al. Br J Cancer. 2024 Feb;130(3):476-482. doi: 10.1038/s41416-023-02534-1. Epub 2023 Dec 22. Br J Cancer. 2024. PMID: 38135713 Free PMC article. Clinical Trial.
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.
Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH. Clifton GT, et al. J Immunother Cancer. 2023 Jun;11(6):e006773. doi: 10.1136/jitc-2023-006773. J Immunother Cancer. 2023. PMID: 37290925 Free PMC article.
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US.
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang SY, Silber A, Leapman MS, Leeds I, Wheeler SB, Spees LP, Gross CP, Lustberg M, Greenup RA, Justice AC, Oeffinger KC, Dinan MA. Kc M, et al. JAMA Netw Open. 2023 Jul 3;6(7):e2323115. doi: 10.1001/jamanetworkopen.2023.23115. JAMA Netw Open. 2023. PMID: 37436746 Free PMC article.
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE; theMednet.org NCI-CCC Tumor Board Program Collaborative Group; Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Kalra M, et al. JMIR Cancer. 2022 May 19;8(2):e33859. doi: 10.2196/33859. JMIR Cancer. 2022. PMID: 35588361 Free PMC article.
Impact of early detection on cancer curability: A modified Delphi panel study.
Schwartzberg L, Broder MS, Ailawadhi S, Beltran H, Blakely LJ, Budd GT, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk BJ, Wong DJ, Campos C, Yermilov I. Schwartzberg L, et al. PLoS One. 2022 Dec 21;17(12):e0279227. doi: 10.1371/journal.pone.0279227. eCollection 2022. PLoS One. 2022. PMID: 36542647 Free PMC article.
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential.
Giner-Calabuig M, De Leon S, Wang J, Fehlmann TD, Ukaegbu C, Gibson J, Alustiza-Fernandez M, Pico MD, Alenda C, Herraiz M, Carrillo-Palau M, Salces I, Reyes J, Ortega SP, Obrador-Hevia A, Cecchini M, Syngal S, Stoffel E, Ellis NA, Sweasy J, Jover R, Llor X, Xicola RM. Giner-Calabuig M, et al. Br J Cancer. 2022 Jun;126(11):1595-1603. doi: 10.1038/s41416-022-01754-1. Epub 2022 Feb 23. Br J Cancer. 2022. PMID: 35197584 Free PMC article.
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
Cecchini M, Walther Z, Wei W, Hafez N, Pilat MJ, Boerner SA, Durecki DE, Eder JP, Schalper KA, Chen AP, LoRusso P. Cecchini M, et al. Cancer Res Commun. 2023 Jun 26;3(6):1113-1117. doi: 10.1158/2767-9764.CRC-22-0485. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37377610 Free PMC article. Clinical Trial.